Background: Hypercholesterolemia is an important risk factor for cardiovascular disease. Orally administered chitosan binds lipids in the small intestine and reduces their absorption. Chitosan has been shown to decrease serum cholesterol in animal and human studies. This study investigated the effectiveness of chitosan in reducing serum cholesterol without concomitant diet therapy. Methods: Ninety female volunteers (age 34 -70 y) with confirmed mild to moderate hypercholesterolemia were enrolled into the study. They were randomly assigned to receive chitosan (1.2 g per day) or placebo in a double-blind manner. Serum lipids, body weight and adverse events were assessed at baseline and after 28 and 56 days of treatment. Subjects maintained their usual diet and documented the type and gross amount of food consumed. Results: Eighty-four subjects (41 chitosan, 43 placebo) were included in the analysis. Chitosan significantly (F ¼ 3.19, P ¼ 0.04) reduced total cholesterol compared to placebo. In a subgroup of subjects with over 60 y of age, chitosan group significantly reduced total and LDL cholesterol (F ¼ 4.21, P ¼ 0.02, and F ¼ 3.46, P ¼ 0.04, respectively) compared with placebo. Adverse effects were few; no serious events were reported. Conclusion: Our results demonstrate that chitosan is safe and effective for lowering cholesterol. However, the effect of chitosan for decreasing cholesterol is mild.
Introduction
In recent years, many clinicians have pointed out that overweight and hypercholesterolemia are important risk factor for cardiovascular disease (Rose et al, 1977; Martin et al, 1986) (Pekkanen et al, 1990; Kannel, 1995) . Furthermore, cholesterol-lowering therapy reduces the risk of coronary heart disease and cerebrovascular accidents in hyperlipidemic patients who are free of previous heart disease or stroke (Shepherd et al, 1995; Bucher et al, 1998) . Regular physical exercise or decreased consumption of total energy and fat are effective in reducing serum cholesterol. Unfortunately, daily exercise or dieting frequently fails, due to poor compliance. HMG-CoA reductase inhibitors have been shown to reduce the risk of coronary events or cerebrovascular disease by lowering cholesterol levels (Sacks et al, 1996; Bucher et al, 1998) . However, HMG-CoA reductase inhibitors have side effects such as myopathy with or without rhabdomyolysis (Lee & Maddix, 2001; Moghadasian et al, 2000) .
Chitosan, a natural polysaccharide of b-1,4-linked glucosamine residues, is a biopolymer obtained primarily from the exoskeletons of crustaceans. Hydrolysis of chitin from shrimps and crabs results in deacetylation of the aminoacetyl groups and yields chitosan (Muzzarelli et al, 1994) . When ingested, chitosan develops an HCl-layer in the stomach. As capsulated particles of chitosan move into the duodenum, the HCl-layer becomes diluted and the chitosan particles form agglomerates with fatty acids and cholesterol, thus reducing lipid absorption from the gastrointestinal tract. Studies in primates have shown that chitosan can increase the amount of fat eliminated in the stool (Sugano et al, 1980; Ebihara & Schneeman, 1989) . This finding led to the use of chitosan as a dietary supplement for weight loss or serum cholesterol reduction. Studies in rats also demonstrated the cholesterol-reducing activity of dietary chitosan (Sugano et al, 1980; Gallaher et al, 2000) . However, a double-blind, randomized, placebo-controlled clinical study did not find significant differences in body mass index, serum cholesterol or triglycerides in subjects receiving chitosan for four weeks, compared to those receiving placebo (Pittler et al, 1999) . In contrast, other authors reported that chitosan significantly lowered serum LDL cholesterol after 8 weeks of treatment (Wuolijoki et al, 1999) . This study was per-protocol analysis intended to investigate whether oral chitosan can reduce total and LDL serum cholesterol in normal healthy females who maintain their usual diet.
Methods
Women with mild to moderate hypercholesterolemia were recruited via an advertisement. All subjects provided written informed consent. The study was approved by the Screening Committee for Alternative Medicine at the Shimane Institute of Health Science and conducted. An individual who was not involved in this study performed block randomization. The randomization code was sealed in an envelope, and broken just after the study of the trial. Subjects taking drugs that could affect lipid metabolism or cholesterol levels (eg HMGCoA reductase inhibitors, cholestyramine, clofibrate, steroids or beta-blockers) were excluded. Liver or renal disease, poorly controlled hypertension, diabetes mellitus, heart failure, pregnancy or lactation were also grounds for exclusion. Subjects were asked to maintain their usual diet and document the type and gross amounts of food consumed. Food consumption was classified into 16 food groups (milk, eggs, meat, fish, beans, vegetables, seaweed, potatoes, fruit, grain, sweets, alcohol, soup, pickles, ham and deep-fried foods). For each food group, consumption was divided into three grades (much, average and little).
Chitosan capsules (Koyo Chemical Co. Ltd, Tokyo, Japan) contained 200 mg of chitosan. The actual amount of chitosan was 199.1 AE 6.7(mean AE s.d.) mg. Chitosan viscosity was 160 mPa s, and the extent deacetylation was 89.5%. Placebo capsules contained 300 mg of lactose. There was no difference between chitosan capsule and placebo capsule in the color, size, form, smell or taste. All subjects received three capsules of chitosan or placebo twice daily after a meal for 56 consecutive days.
Fasting blood samples were taken at baseline and after 28 days and 56 days of treatment: total cholesterol, highdensity lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride levels were measured. Blood pressure, body weight and body mass index (BMI) were also assessed. Safety was evaluated with serum chemistry profiles, complete blood counts, and changes in physical findings and signs at each study visit.
Because risks for progression of atherosclerosis can now be tabulated based on age, subgroup analysis in subjects over 60 y of age was carried out.
Results were presented as means and standard deviation (s.d.). Changes in lipid variables, body mass index, and fatweight ratio from baseline to 28 and 56 days were analyzed using paired t-tests; analysis of variance (ANOVA) for repeated measures was used to compare intervention and control values. The chi-square test was used to compare inter-group differences of subjects in each treatment group with adverse events. The statistical analyses were performed using Statview (SAS Institute Inc.).
Results
Ninety female volunteers entered this study and were randomly assigned to the placebo (46) or chitosan (44) group. Eighty-four subjects (41 chitosan, 43 placebo) were included in the data analysis: three withdrew from the study for personal reasons after the first visit, and three who had taken less than 80% of their allotted medication by their second visit were excluded (Figure 1 ). The compliance of both groups was generally good. The compliance of each subject was at least 80%.
The baseline characteristics of the subjects in the chitosan and placebo groups were not significantly different (Table 1) . There were no significant changes in weight, BMI and blood pressure in either the chitosan or placebo groups after 4 or 8 weeks of treatment. No differences between the chitosan and placebo groups were found with respect to food consumption.
Compared with baseline, 8 weeks of chitosan therapy produced a statistically significant reduction in total cholesterol (241 AE 25 mg=dl to 233 AE 25 mg=dl, P ¼ 0.04). Significant differences were observed between the curves of chitosan and placebo groups (F ¼ 3.19, P ¼ 0.04; Figure 2 ). In the chitosan group, LDL cholesterol also significantly decreased 152 AE 26 mg=dl at baseline to 143 AE 22 mg=dl at 8 weeks, (P ¼ 0.007). However, no significant differences were observed Figure 1 Flow chart for the number of the subjects.
Chitosan decreases total cholesterol
H Bokura and S Kobayashi between the curves of two groups (F ¼ 2.73, P ¼ 0.07; Figure 3 ). Although a significant decrease from baseline HDL cholesterol was also observed for both the placebo and chitosan study groups (at both the 4 and 8 week assessments), HDL cholesterol was maintained within normal limits. No significant differences were observed between two curves (F ¼ 0.89,
Triglyceride levels did not change significantly in either the placebo or chitosan groups. In a subgroup of subjects over 60 y of age (16 chitosan, 20 placebo), total cholesterol tended to decrease more in the chitosan group than in the placebo group (Table 2 and Figure 4 ). After 4 and 8 weeks of treatment, total cholesterol Closed and open circle are showed in chitosan group and placebo group, respectively. *P < 0.05 for the comparison with the baseline. A significant differences were observed between the curves of chitosan and placebo groups (P ¼ 0.04).
Figure 3
Changes of LDL-cholesterol in all subjects treated with chitosan (n ¼ 41) and placebo (n ¼ 43). Closed and open circle are showed in chitosan group and placebo group, respectively. *P < 0.05, **P < 0.01 for the comparison with the baseline. Chitosan, n ¼ 16; placebo, n ¼ 20. *P < 0.05; **P < 0.01 for the comparison with the baseline.
Chitosan decreases total cholesterol H Bokura and S Kobayashi decreased in the chitosan group from 241 AE 30 mg=dl to 232 AE 27 mg=dl and 226 AE 29 mg=dl, respectively, while in the placebo group total cholesterol changed from 237 AE 26 mg=dl to 235 AE 32 mg=dl and 242 AE 27 mg=dl, respectively. There was a significant difference between two curves of the chitosan and placebo groups (F ¼ 4.21, P ¼ 0.02). LDL cholesterol at baseline was 153 AE 28 mg=dl in the chitosan group and 152 AE 27 mg=dl in the placebo group, at 4 weeks was 144 AE 25 mg=dl in the chitosan group and 148 AE 30 mg=dl in the placebo group, and 135 AE 22 mg=dl and 151 AE 24 mg=dl, respectively at 8 weeks. A significant (F ¼ 3.46, P ¼ 0.04) difference was observed between the curves of two groups ( Figure 5 ). HDL cholesterol and triglycerides did not change significantly in either group. Adverse events are shown in Table 3 . Nine adverse events were observed during the 8 week study period: five in the chitosan group and four in the placebo group. One subject in the placebo group complained of abdominal fullness and dropped out of the study. Three subjects in the chitosan group complained of thirst, the most frequent adverse event for chitosan. Changes in laboratory parameters were very small and transient; subjects with laboratory abnormalities did not show any associated symptoms.
Discussion
Although the recommended dose of chitosan is 2 -3 g per day (Pittler et al, 1999) , we found that, compared with placebo, 1.2 g per day of chitosan produced a statistically significant decrease in total cholesterol in healthy women volunteers after 8 weeks. These effects were more prominent in elderly individuals. Total and LDL cholesterol significantly decreased in the chitosan group in the over 60 y subgroup. Arai et al (2000) reported that LDL cholesterol levels in Japanese women increase significantly with menopause. High total and LDL cholesterol, or low HDL cholesterol have been reported to be significant coronary risk factors (Wilson & Kannel, 1993; Sheu et al, 2000) . The rate of coronary heart disease among women increases with age. The data from large-scale population studies suggest that around the time of the menopause, LDL cholesterol levels increase by approximately 15 -25% (Davidson et al, 2002) . It is very important to control serum lipids in elderly women with hypercholesterolemia, for primary prevention of coronary heart disease (Rackley, 2002) . For prevention of coronary disease, optimal LDL cholesterol is reported as < 100 mg=dl in both women and men (Sharrett et al, 2001) . Our results show that chitosan may have value in the therapy of elderly women with hypercholesterolemia. Previous studies have shown that chitosan reduced serum LDL cholesterol (Yihua & Binglin, 1997; Wuolijoki et al, 1999) , as also seen in our findings. Wuolijoki et al (1999) reported a lack of significant differences between chitosan and placebo with respect to the decrease in total cholesterol in their double-blind, placebo controlled trial. They assumed that they had few registered subjects who had normal serum cholesterol levels. For this reason they thought the decrease of total cholesterol was relatively small. Pittler et al (1999) pointed out that, after 4 weeks of treatment, total serum cholesterol was not significantly different in subjects receiving chitosan than in those receiving placebo. Our study also indicated that total serum cholesterol did not change Figure 4 Changes of total cholesterol in over 60 y subjects treated with chitosan (n ¼ 16) and placebo (n ¼ 20) . Closed and open circle are showed in chitosan group and placebo group, respectively. *P < 0.05 for the comparison with the baseline. A significant difference (P ¼ 0.02) was observed between two curves of groups. Figure 5 Changes of LDL-cholesterol in over 60 y subjects treated with chitosan (n ¼ 16) and placebo (n ¼ 20) . Closed and open circle are showed in chitosan group and placebo group, respectively. *P < 0.05, **P < 0.01 for the comparison with the baseline. A Significant difference (P ¼ 0.04) was observed between two curves of groups. Chitosan decreases total cholesterol H Bokura and S Kobayashi significantly with 4 weeks of chitosan treatment; a significant decrease was, however, observed after 8 weeks. These findings suggest that the beneficial effect of chitosan may require 8 weeks to appear, perhaps because chitosan does not reduce cholesterol synthesis but reduces lipid absorption from the gastrointestinal tract. However, many subjects were still hypercholestrolemic in terms of total and LDL cholesterol. The effect of chitosan for decreasing cholesterol is thought to be weaker than HMG-CoA reductase inhibitors. HDL cholesterol levels were significantly decreased in both the chitosan and placebo groups. According to the food consumption records, this may be due to a relatively low-fat diet. In any case, chitosan would be expected to reduce absorption of cholesterol from the gastrointestinal tract. Nonetheless, serum HDL cholesterol remained normal in both groups after 8 weeks. A future direction of study should be to investigate the effect of chitosan on patients with low serum HDL cholesterol level.
As in previous reports, serum triglycerides did not change in the chitosan group. Previous studies also found that triglycerides were either slightly increased (Pittler et al, 1999) or not significantly different in subjects receiving chitosan compared with placebo (Wuolijoki et al, 1999) .
Although previous studies demonstrated that oral chitosan was effective for body weight reduction (Colombo & Sciutto, 1996; Giustina & Ventura, 1995; Veneroni et al, 1996) , this trial did not show an effect of chitosan on body weight or BMI. The preceding trials were, however, conducted with hypocaloric diets. Pitter et al (1999) reported in their randomized, double-blind trial that oral chitosan did not reduce body weight in the absence of dietary alteration. As we did not require the subjects to follow hypoenergetic diets, we consequently found no reduction in body weight.
In conclusion, our results suggest that chitosan is a safe and significantly reducing serum total cholesterol, especially in elderly women. However, the effect of chitosan on decreasing total and LDL cholesterol is mild.
